A Toronto Stock Exchange logo is seen in Toronto in this file photo.© Mark Blinch / Reuters
Globe editors have posted this research report with permission of Thomson Reuters I/B/E/S. This should not be construed as an endorsement of the report's recommendations. For more on The Globe's disclaimers please read here. The following is excerpted from the report:
EARNINGS HIGHLIGHTS
Q1 2017 Y/Y Blended Earnings Growth Estimates:
- TSX Composite = 29.0 per cent
- Ex-Energy = 15.4 per cent
- Valeant Pharmaceuticals = -33.8 per cent
- Healthcare Ex- VRX = 13.5 per cent
- TSX Composite Ex-VRX = 30.1 per cent
Q1 2017 Performance vs. Earnings Expectations:
Eighty-nine per cent of the TSX Composite companies have reported Q1 2017 EPS. Of the 218 companies in the index that have reported earnings to date for Q1 2017:
- 46.8 per cent reported above analyst expectations
- 40.4 per cent reported below analyst expectations
REVENUE HIGHLIGHTS
Q1 2017 Y/Y Blended Revenue Growth Estimates:
- TSX Composite = 9.6 per cent
- Ex-Energy = 4.6 per cent
- Valeant Pharmaaceuticals = -4.1 per cent
- Healthcare Ex-Valeant Pharmaceuticals = 5.1 per cent
- TSX Composite Ex-Valeant Pharmaceuticals = 9.7 per cent
Q1 2017 Performance vs. Revenue Expectations:
Of the TSX Composite companies that have reported revenue to date for Q1 2017:
- 52.9 per cent reported above analyst expectations
- 46.2 per cent reported below analyst expectations
Click here to see a full copy of the Thomson Reuters I/B/E/S TSX Composite Earnings Scorecard.
Globe app users click here for the full report
Read other research reports here.